MYO - Myomo, Inc.
NYSE
->
Healthcare
->
Medical Devices
Boston,
United States
Type: Equity
MYO price evolution
MYO
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2.38 | $2.52 | $1.64 | $1.55 |
| Inventory | $1.8 | $1.48 | $1.34 | $1.57 |
| Total current assets | $13.65 | $16.04 | $12.63 | $12.91 |
| Long term investments | ||||
| Property, plant & equipment | $0.84 | $0.89 | $0.45 | $0.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $14.58 | $17.05 | $13.3 | $13.74 |
| Current liabilities | ||||
| Accounts payable | $1.07 | $1.22 | $0.77 | $0.91 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.48 | $5.78 | $4.34 | $3.93 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.59 | $6.03 | $4.48 | $4.1 |
| Shareholders' equity | ||||
| Retained earnings | -$96.93 | -$94.47 | -$92.44 | -$91.43 |
| Other shareholder equity | $0.08 | -$0.01 | $0.04 | $0.11 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.24 | |||
| Short term investments | ||||
| Net receivables | $2.38 | $1.9 | $1.96 | $0.92 |
| Inventory | $1.8 | $1.4 | $0.81 | $0.71 |
| Total current assets | $13.65 | $9.22 | $19.19 | $14.45 |
| Long term investments | ||||
| Property, plant & equipment | $0.84 | $0.7 | $0.91 | $0.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.26 | |||
| Total investments | ||||
| Total assets | $14.58 | $10.16 | $20.1 | $14.71 |
| Current liabilities | ||||
| Accounts payable | $2.19 | $1.32 | $0.72 | $2.85 |
| Deferred revenue | $0 | |||
| Short long term debt | ||||
| Total current liabilities | $5.48 | $3.6 | $4.28 | $2.87 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.27 | |||
| Total debt | ||||
| Total liabilities | $5.59 | $3.8 | $4.69 | $3.14 |
| Shareholders' equity | ||||
| Retained earnings | -$96.93 | -$88.78 | -$78.06 | -$67.69 |
| Other shareholder equity | $0.08 | $0.04 | -$0.06 | -$0.02 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.87 | |||
| Cost of revenue | ||||
| Gross Profit | $2.58 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.32 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.08 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$2.81 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.58 | $3.84 | $2.44 | |
| Cost of revenue | ||||
| Gross Profit | $4.98 | $2.42 | $1.72 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $16.09 | $13.63 | $12.97 | |
| Operating income | -$10.5 | -$10.79 | -$10.53 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.47 | $0.11 | -$0.18 | |
| Net income | ||||
| Net income | -$11.56 | -$10.71 | -$10.32 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.31 | -$0.3 | -$0.25 | -$0.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $13.17 | |||
| Effect of exchange rate | -$0.03 | -$0.02 | -$0.01 | -$0.01 |
| Change in cash and equivalents | -$8.1 | -$5.29 | -$2.58 | $3.28 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$11.56 | -$10.71 | -$10.32 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.03 | -$10.34 | -$9.61 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.33 | -$0.05 | -$0.05 | -$0.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $13.17 | $16.78 | $8.32 | $3.34 |
| Effect of exchange rate | -$0.01 | -$0 | ||
| Change in cash and equivalents | $3.28 | $7.7 | -$2.08 | -$6.4 |
News
|
Director Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)
GuruFocus.com via Yahoo Finance
18 Mar 2024
|
|
Myomo, Inc. (AMEX:MYO) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
8 Mar 2024
|
|
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
7 Mar 2024
|
|
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
Zacks via Yahoo Finance
21 Dec 2023
|
|
Growth Stocks Under $50 for December 2023
Investopedia
15 Dec 2023
|
|
Top Penny Stocks for Q4 2023
Investopedia
1 Dec 2023
|
|
Is Myomo (MYO) a Hidden Gem or a Value Trap? A Comprehensive Analysis
GuruFocus.com via Yahoo Finance
28 Aug 2023
|
|
Myomo Inc (MYO): A Hidden Gem or a Potential Value Trap?
GuruFocus.com via Yahoo Finance
24 Aug 2023
|
|
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
9 Aug 2023
|
|
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
Zacks via Yahoo Finance
5 Jul 2023
|
Fundamentals
| Market cap | $86.56M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 27.14M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.49 |
| Quick ratio | 2.16 |